Default company panoramic image
Logo

EicOsis, LLC

EicOsis focuses on developing safe and effective, non-narcotic therapies for moderate to severe pain and inflammation in animals and man.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Davis, CA, USA
  • Currency USD
  • Founded December 2011
  • Employees 7
  • Incorporation Type LLC

Company Summary

EicOsis is developing a first-in-class therapy of a once daily, oral treatment for neuropathic and inflammatory pain in humans and animals. Pain is an enormous emotional and economic burden. Current therapies have dose limiting side effects in addition to being ineffective in more than 3 of 4 patients. EicOsis discovered a novel enzyme target to alleviate pain without the dose limiting or narcotic side effects that exist in current treatments.

Team

  • Dr. Hammock is a Distinguished Professor at the University of California, Davis. Dr. Hammock was elected as a member to the National Academy of Sciences, US (1999). He has over 30 years of extensive experience in the field of eicosanoids that yielded over 800 publications and 100 issued patents on synthesis, pharmacology and biological action of eicosanoids and soluble epoxide hydrolase inhibitors.

  • 42482e88 9810 4c9f 84a2 82175685ad20
    Clinical Development

    Dr. Schmidt is head of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs. He is the Parliamentarian and a Past-President of the Eastern Pain Association, and has over 25 years of pharmaceutical experience specifically in the development of novel analgesic drugs. Dr. Schmidt currently sits on Scientific Advisory Boards of 1 academic laboratory and 4 biotech companies.

  • E1ce419b 1751 4884 91e2 c31ed430e898
    VP Development

    Dr. Giri, has extensive experience in a number of areas including pharmaceutical Research and Development, FDA relations and business development. He was VP of Research and Drug Development where he developed, pirfenidone, for treatment of pulmonary fibrosis. He later became the President and CEO of Solanan where he guided all research endeavors of the company to develop a small molecule for treating septic shock in humans.

  • 21807df8 49d1 4918 9f58 e7b9b24dccca
    VP Research

    Dr. Inceoglu is a co-founder of Eicosis. He discovered the analgesic and anti-convulsant effects of epoxygenated eicosanoids. Dr. Inceoglu served as Chief Scientific Officer at TBT Ltd, Ankara, Turkey and is a recipient of J&J Pharmaceutical’s Innovative Research Award (2008). Dr. Inceoglu has authored 40 peer reviewed publications and 4 issued patents. His research is focused on eicosanoid biology with an emphasis of neurological systems.

  • Ff246318 5b5b 4c97 8573 270bf43f7b60
    Project Manager

    Mrs. McReynolds specializes in Project Management for start-up and semi-virtual biotech companies. She managed the preclinical efforts at Miikana that resulted in the identification of a small molecule IND candidate that is currently in phase 2 clinical trials. She also managed the research efforts from IND-enabling studies through Phase II clinical trials at Arete Therapeutics.

  • E9f1bb0b 53fe 4a63 8577 650b99ffc435
    VP Pharmacology

    Dr. Buckpitt is a Professor at the University of Califorania, Davis. Dr. Buckpitt currently specializes in pharmacokinetics, and absorption, distribution, metabolism, and excretion as well as site selective toxicity of the lung and kidney.

  • Default avatar
    Karen Wagner
    Principal Scientist

    Dr. Wagner is a post doctoral scholar at the University of California Davis. Dr. Wagner received her Ph.D. in Pharmacology and Toxicology from the University of Califorina Davis in 2012. She then served as a Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow. She has numerous peer reviewed publications investigating pain and therapeutics. Her research focus is on neurobiology and eicosanoids.

  • F36195c5 6245 4e5a bade 6e4c4cce3fe4
    VP Pharmacology

    Dr. Buckpitt is a Professor at the University of Califorania, Davis. Dr. Buckpitt currently specializes in pharmacokinetics, and absorption, distribution, metabolism, and excretion as well as site selective toxicity of the lung and kidney.

Advisors

  • Default avatar
    Gilles Attia, DLA Piper
    Lawyer
    Unconfirmed